Regeneron Pharmaceuticals will hear back from the FDA this month on an approval decision for one of its most promising drug candidates, and investors should be excited about the potential the drug holds.
Regeneron Pharmaceuticals will hear back from the FDA this month on an approval decision for one of its most promising drug candidates, and investors should be excited about the potential the drug holds.